Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study)

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study) Am J Cardiovasc Drugs (2013) 13:47–56 DOI 10.1007/s40256-013-0004-9 OR IGINAL RESEARCH ARTIC L E Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study) An Open-Label Observational Study • • • Jeong Bae Park Ki-Chul Sung Seok-Min Kang Eun Joo Cho Published online: 24 January 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Abstract collected using electronic case report forms. Written Background Angiotensin II receptor blockers (ARBs) informed consent forms were obtained from all patients. play a key role in hypertension therapy. Recently, fima- Results A total of 14,151 patients (50.7 % males; mean age sartan, the ninth ARB, was developed, but its safety and 59 ± 12 years) were evaluated, of whom 37.9 % were never efficacy have not been well established. treated with fimasartan, 53.5 % were switched to fimasartan, Objective The objective of this study was to determine and 8.5 % had fimasartan added to their treatment. Overall, whether age, sex, concomitant disease, and current anti- fimasartan reduced systolic blood pressure (SBP) from hypertensive medications affect the safety and efficacy of 145.4 ± 18.1 to 126.8 ± 12.6 mmHg and diastolic blood fimasartan in patients with arterial hypertension. pressure http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study)

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/safety-and-efficacy-of-fimasartan-in-patients-with-arterial-GN7z5RleGK

References (51)

Publisher
Springer Journals
Copyright
Copyright © 2013 by The Author(s)
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-013-0004-9
pmid
23344912
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2013) 13:47–56 DOI 10.1007/s40256-013-0004-9 OR IGINAL RESEARCH ARTIC L E Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study) An Open-Label Observational Study • • • Jeong Bae Park Ki-Chul Sung Seok-Min Kang Eun Joo Cho Published online: 24 January 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Abstract collected using electronic case report forms. Written Background Angiotensin II receptor blockers (ARBs) informed consent forms were obtained from all patients. play a key role in hypertension therapy. Recently, fima- Results A total of 14,151 patients (50.7 % males; mean age sartan, the ninth ARB, was developed, but its safety and 59 ± 12 years) were evaluated, of whom 37.9 % were never efficacy have not been well established. treated with fimasartan, 53.5 % were switched to fimasartan, Objective The objective of this study was to determine and 8.5 % had fimasartan added to their treatment. Overall, whether age, sex, concomitant disease, and current anti- fimasartan reduced systolic blood pressure (SBP) from hypertensive medications affect the safety and efficacy of 145.4 ± 18.1 to 126.8 ± 12.6 mmHg and diastolic blood fimasartan in patients with arterial hypertension. pressure

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Jan 24, 2013

There are no references for this article.